Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
- Presentation at a prestigious event like BIO International Convention increases visibility and credibility.
- Opportunity for one-on-one meetings with potential partners and investors can lead to strategic collaborations.
- Scheduled presentation by a top executive, Sanjeev Redkar, PhD, showcases strong leadership.
- No new clinical or financial data disclosed in the announcement.
- The press release does not specify any milestones or updates on current projects.
FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
BIO International Convention (June 3-6, 2024)
Format: In-person
Location: San Diego, California
Presentation Date: Tuesday, June 4, 2024
Location: Theater 2 located in Hall A of the Exhibition Hall at the San Diego Convention Center
Presentation Time: 3:15 p.m.
Presenter: Sanjeev Redkar, PhD, President and Executive Director of Apollomics
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact brandon.weiner@westwicke.com.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com.
CONTACTS
Investor Relations
Peter Vozzo
ICR Westwicke
Peter.Vozzo@westwicke.com
+1-443-213-0505
Media Relations
Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com
+1-646-866-4012
FAQ
When will Apollomics present at the 2024 BIO International Convention?
Who is presenting for Apollomics at the 2024 BIO International Convention?
Where is the 2024 BIO International Convention being held?
How can I schedule a meeting with Apollomics' management at the 2024 BIO International Convention?
